

Product Licence Number	Company Name	Product Name	Active Ingredients	Indications	Date of Authorisation
	SmithKline & French Laboratories; SmithKline Beecham Pharmaceuticals			induced by cytostatic therapy.	
10592/0051	SmithKline Beecham Plc t/a Beecham Research; Bencard; Bridge; SmithKline & French Laboratories; SmithKline Beecham Pharmaceuticals	Co-Amoxiclav Dispersible Tablets 375mg	Amoxicillin Trihydrate Equivalent to Amoxicillin EP 250mg Potassium Clavulanate Equivalent to Clavulanic Acid HSE 125 mg	Prescription Only Medicine For the short term treatment of Bacterial Infections at the following sites: Upper Respiratory Tract infections (including ENT) EG, Tonsillitis, Sinusitis, Otitis Media. Lower Respiratory Tract Infections EG Acute and Chronic Bronchitis, Lobar and Bronchopneumonia. Genito-Urinary Tract Infections EG Cystitis, Urethritis, Pyelonephritis. Skin and Soft Tissue Infections Bone and Joint Infections EG Osteomyelitis Dental Infections EG Dentoalveolar Abscess Other Infections EG Septic Abortion, Puerperal Sepsis, Intra-Abdominal Sepsis.	1st November 1994
10592/0052	SmithKline Beecham Plc t/a SmithKline Beecham Pharmaceuticals and/or SmithKline Beecham Vaccines	'Fluarix'	Purified antigen fractions of inactivated Influenza viruses (cultivated in embryonated hen's eggs) corresponding to WHO selected strains (1994): A/Shangdong/9/93 X-121 (H ₁ N ₂) HSE 15.0 ug* A/Singapore/6/86 - like strain (H ₁ N ₂) HSE 15.0 ug* B/Panama/45/90 HSE 15.0 ug* *Expressed as µg of haemagglutinin per 0.5ml dose	Prescription Only Medicine Prophylaxis against influenza in adults and children over six months of age. It is recommended in those groups regarded as being at special risk, especially the elderly (over 60 years of age) and/or subjects with the following: Diseases of the cardiovascular system, metabolic diseases (diabetes), cystic fibrosis, chronic respiratory diseases and chronic renal insufficiency, congenital or acquired immune deficiency.	19th August 1994
10622/0003	Cusi (UK) Limited	Cusitube	White soft paraffin BP 60.0% w/w Liquid paraffin EP 30.0% w/w Wool fat EP 10.0% w/w	Pharmacy Medicine As adjunctive therapy to lubricate and protect the eye in conditions such as exposure keratitis, decreased corneal sensitivity, recurrent corneal erosions, keratitis sicca, ophthalmic surgery and non-ophthalmic surgery.	16th August 1994
10949/0089	Glaxo Pharmaceuticals UK Limited	Volmax Tablets 4mg	Salbutamol Sulphate BP 4.82 mg	Prescription Only Medicine For the treatment of reversible airways obstruction due to asthma. Because of their controlled release formulation they may be helpful in the management of nocturnal asthma.	1st August 1994
10949/0090	Glaxo Pharmaceuticals UK Limited	Volmax Tablets 8mg	Salbutamol Sulphate BP 9.64 mg	Prescription Only Medicine See PL/10949/0089	1st August 1994
10949/0231	Glaxo Pharmaceuticals UK Limited	Imigran Tablets 100 MG	Sumatriptan Succinate HSE 140.00 MG* *Equivalent to 100MG Sumatriptan base	Prescription Only Medicine For the acute relief of migraine attacks with or without aura.	1st August 1994
111570002	Novex Pharma Limited	Danlax Suspension (Co-Danthramer Suspension)	Danthron BP 25.0 mg Poloxamer 188 NF 200.0 mg	Prescription Only Medicine Constipation in the elderly, analgesic induced constipation in the terminally ill in all age groups, prophylaxis of analgesic induced	11th August 1994